TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10487566

Group type: EXPERIMENTAL
Intervention: WBRT plus radiosurgery
Number of subjects: 27

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 27
Study: 8711678

Group type: EXPERIMENTAL
Intervention: Methacholine provocation testing (PD15)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Peak expiratory flow (PEF) monitoring
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in one second (FEV1%)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (EXE)
Number of subjects: 495
Study: 1885286

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cimetidine with weight loss
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo with weight loss
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7114936

Group type: EXPERIMENTAL
Intervention: Limb-sparing resection plus adjuvant radiation therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 43
Study: 31075187

Group type: EXPERIMENTAL
Intervention: Evobrutinib 25 mg once daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg once daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Evobrutinib 75 mg twice daily
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 267
Study: 30075776

Group type: EXPERIMENTAL
Intervention: Palliative care for patients with a substance use disorder
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with patients and proxies
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thematic analysis of interviews
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SWOT analysis of group interview data
Number of subjects: 10
Study: 26522674

Group type: EXPERIMENTAL
Intervention: Weight-loss and lifestyle intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 24643924

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.2 mg) with 0.5% hyperbaric bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (0.5% hyperbaric bupivacaine only)
Number of subjects: 30
Study: 22616980

Group type: EXPERIMENTAL
Intervention: Early amniotomy (EA)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Late amniotomy (LA)
Number of subjects: 143
Study: 19085908

Group type: EXPERIMENTAL
Intervention: PEG IFN alfa-2b (PEG 2b) plus ribavirin (RBV)
Number of subjects: 182

Group type: COMPARATOR
Intervention: PEG IFN alfa-2a (PEG 2a) plus ribavirin (RBV)
Number of subjects: 182
Study: 17452537

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 572
Study: 15250647

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention in a rehabilitation center
Number of subjects: 731

Group type: COMPARATOR
Intervention: Usual care provided by occupational or primary health care services
Number of subjects: 731
Study: 11096224

Group type: EXPERIMENTAL
Intervention: Rivastigmine (6-12 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9419078

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upright position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dark condition
Number of subjects: 0
Study: 8469820

Group type: EXPERIMENTAL
Intervention: Dobutamine (DBT1) at 5 micrograms/kg/min for 30 min
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dopamine (DOP2) at a dose sufficient to induce a similar rise in MAP as DBT1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal saline infusion (NS1 and NS2)
Number of subjects: 7
Study: 3081208

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 6.3 mmol/l (113.5 mg/100 ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 2.9 mmol/l (52.3 mg/100 ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 1.8 mmol/l (32.4 mg/100 ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 6.1 mmol/l (109.9 mg/100 ml) after intravenous glucose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Period C (1.8 mmol/l)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Period A (6.3 mmol/l) and Period B (2.9 mmol/l)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Period D (6.1 mmol/l)
Number of subjects: 16
Study: 3169372

Group type: EXPERIMENTAL
Intervention: Doxofylline (200 mg intravenously over 15 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Doxofylline
Number of subjects: 10
Study: 31859034

Group type: EXPERIMENTAL
Intervention: 11+ Kids warm-up programme
Number of subjects: 962

Group type: COMPARATOR
Intervention: Standard warm-up programme (Control)
Number of subjects: 962
Study: 31190496

Group type: EXPERIMENTAL
Intervention: Auricular point sticking intervention applied at specific auricular points (Shenmen, Shen, Wei, Gan, Pi, Pizhixia, E, Nie, Zhen), 3-5 minutes per point, 5 times a day for 1 week post-surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group received routine preoperative guidance and visits
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Auricular point sticking intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 28497402

Group type: EXPERIMENTAL
Intervention: Resection of the primary tumor plus systemic chemotherapy after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic chemotherapy alone
Number of subjects: 0
Study: 26399752

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 143

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: NIPPV (subgroup with surfactant therapy)
Number of subjects: 143

Group type: COMPARATOR
Intervention: NCPAP (subgroup with surfactant therapy)
Number of subjects: 143
Study: 23433347

Group type: EXPERIMENTAL
Intervention: Diabetes specialist/educator consultation support (active for 2 months, passive for 10 months) and community retail pharmacist support (1-hour insulin-initiation session)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care (no additional support)
Number of subjects: 151
Study: 21584948

Group type: EXPERIMENTAL
Intervention: Arformoterol (7.5 µg/dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arformoterol (15 µg/dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levalbuterol (0.63 mg/dose)
Number of subjects: 0
Study: 19084158

Group type: EXPERIMENTAL
Intervention: PAR-Pa infection
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Longer stay in ICU
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Localized PAR-Pa infections
Number of subjects: 28
Study: 16585472

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment for Substance Abuse in Severe and Persistent Mental Illness (BTSAS)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Supportive Treatment for Addiction Recovery (STAR)
Number of subjects: 129
Study: 14689372

Group type: EXPERIMENTAL
Intervention: Intravenous angiotensin II infusion (0-512 ng/minute) during placebo therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous angiotensin II infusion during telmisartan therapy (40-80 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Telmisartan therapy (40-80 mg/day)
Number of subjects: 10
Study: 10868708

Group type: EXPERIMENTAL
Intervention: Pulmicort Turbuhaler
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pulmicort Nebuhaler
Number of subjects: 72
Study: 9183594

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 28
Study: 1607733

Group type: EXPERIMENTAL
Intervention: HCR therapy (hyperthermo-chemoradiotherapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: CR therapy (chemoradiotherapy without hyperthermia)
Number of subjects: 53
Study: 3885454

Group type: EXPERIMENTAL
Intervention: Tinidazole (1600 mg) and Doxycycline (400 mg)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Tinidazole (1600 mg) and Placebo
Number of subjects: 267
Study: 30290817

Group type: EXPERIMENTAL
Intervention: Cisplatin‐etoposide chemotherapy (maximum of six cycles)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (250 controls)
Number of subjects: 250
Study: 26228645

Group type: EXPERIMENTAL
Intervention: Propranolol (group P, n = 33)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Venlafaxine (group V, n = 31)
Number of subjects: 64
Study: 24865132

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg once a day
Number of subjects: 1331

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1331
Study: 22583605

Group type: EXPERIMENTAL
Intervention: Whole-pelvic external-beam radiation therapy of 50 Gy/25 fractions and high-dose-rate intracavitary brachytherapy of 24 Gy/4 fractions without chemotherapy
Number of subjects: 59
Study: 20108006

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study: 18316519

Group type: EXPERIMENTAL
Intervention: ST-246 (500 mg, 1,000 mg, 2,000 mg for fasting; 1,000 mg for nonfasting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ST-246
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15944076

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 12727125

Group type: EXPERIMENTAL
Intervention: Panic control treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Panic control with in vivo exposure
Number of subjects: 68
Study: 10975629

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA) plus contingent vouchers, n = 125
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control treatments, n = 65
Number of subjects: 190
Study: 9366300

Group type: EXPERIMENTAL
Intervention: M-CAVI (methotrexate, carboplatin, and vinblastine)
Number of subjects: 47

Group type: COMPARATOR
Intervention: M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 47
Study: 1439854

Group type: EXPERIMENTAL
Intervention: Yohimbine (YOH) ointment, 5 mg applied twice daily at the balanopreputial sulcus.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Papaverine delivered with cavernous bodies by a Controlled Transdermal Drugs Administration System (C.T.D.A.S.).
Number of subjects: 62
Study: 3754043

Group type: EXPERIMENTAL
Intervention: Neodymium YAG laser (Nd:YAG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Argon laser
Number of subjects: 38
Study: 29290089

Group type: EXPERIMENTAL
Intervention: VCMX
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SCTG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PROMs
Number of subjects: 20
Study: 28815629

Group type: EXPERIMENTAL
Intervention: Detoxified alcohol-dependent patients (AUD)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Young adult social drinkers
Number of subjects: 410
Study: 25075894

Group type: EXPERIMENTAL
Intervention: Technique as described by Stevens (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Technique modified from Paley (group B)
Number of subjects: 18
Study: 24304605

Group type: EXPERIMENTAL
Intervention: Krill oil (600 mg of n-3 PUFA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fish oil (600 mg of n-3 PUFA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (corn oil)
Number of subjects: 24
Study: 21423000

Group type: EXPERIMENTAL
Intervention: Enteral fish oil (9.75 g eicosapentaenoic acid and 6.75 g docosahexanoic acid daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enteral fish oil
Number of subjects: 90
Study: 18176174

Group type: EXPERIMENTAL
Intervention: Calcitriol administration during 1 year
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no calcitriol)
Number of subjects: 16
Study: 16570433

Group type: EXPERIMENTAL
Intervention: Guan-moxibustion plus acupuncture
Number of subjects: 157

Group type: COMPARATOR
Intervention: Suspended moxibustion plus acupuncture
Number of subjects: 157
Study: 14563500

Group type: EXPERIMENTAL
Intervention: Chinese herbal remedy (four tablets, three times a day for 30 days)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo (identical tablets, three times a day for 30 days)
Number of subjects: 237
Study: 10213724

Group type: EXPERIMENTAL
Intervention: Trial without a placebo arm
Number of subjects: 436

Group type: COMPARATOR
Intervention: Trial with a placebo arm
Number of subjects: 436
Study: 8724688

Group type: EXPERIMENTAL
Intervention: Improvement strategy (concierge service)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cycle 2 intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Cycle 2)
Number of subjects: 0
Study: 1684310

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (HD), 60 mg every 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (HD)
Number of subjects: 41
Study: 7201100

Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (16 units per day for 10 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lysine vasopressin
Number of subjects: 14
Study: 31261577

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT) intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study: 28132685

Group type: EXPERIMENTAL
Intervention: Persistent or new-onset ASH
Number of subjects: 1691

Group type: COMPARATOR
Intervention: No association with increased mortality
Number of subjects: 1691
Study: 26564411

Group type: EXPERIMENTAL
Intervention: Mild propofol sedation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Deep propofol sedation
Number of subjects: 48
Study: 24018576

Group type: EXPERIMENTAL
Intervention: Multisession training over 10 days (9 adults/group) for older adults
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multisession training over 10 days (9 adults/group) for young adults
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group of older adults (6 adults/group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group of young adults (6 adults/group)
Number of subjects: 30
Study: 20864613

Group type: EXPERIMENTAL
Intervention: Varenicline (n=250)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo (n=254)
Number of subjects: 504
Study: 19408821

Group type: EXPERIMENTAL
Intervention: Individual oral hygiene instruction
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Group oral hygiene instruction
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination of individual and group oral hygiene instructions
Number of subjects: 104

Group type: COMPARATOR
Intervention: No oral hygiene instruction (Control group)
Number of subjects: 104
Study: 17696684

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg) after pretreatment with placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nicotine gum (4 mg) after pretreatment with 50 mg naltrexone
Number of subjects: 18
Study: 15167602

Group type: EXPERIMENTAL
Intervention: FTY720 (0.25 to 3.5 mg, single oral dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11499124

Group type: EXPERIMENTAL
Intervention: Brief preventive intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-risk controls (normative comparison)
Number of subjects: 0
Study: 9713029

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (25 mg/kg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 7474673

Group type: EXPERIMENTAL
Intervention: Calcium carbonate as the sole phosphate-binding agent during sodium citrate infusion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium carbonate as the sole phosphate-binding agent during calcium infusion.
Number of subjects: 0
Study: 2128881

Group type: EXPERIMENTAL
Intervention: hMG (human menopausal gonadotropin)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FSH (follicle-stimulating hormone)
Number of subjects: 46
Study: 387019

Group type: EXPERIMENTAL
Intervention: Cephaloridine
Number of subjects: 159
Study: 29057579

Group type: EXPERIMENTAL
Intervention: 6 weeks of daily Internet gaming (training group)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Non-gaming condition (training control group)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Excessive Internet gamers
Number of subjects: 119
Study: 28452622

Group type: EXPERIMENTAL
Intervention: 100% cortical FDBA
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 100% cancellous FDBA
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 50%/50% cortico-cancellous FDBA
Number of subjects: 66
Study: 25881639

Group type: EXPERIMENTAL
Intervention: Massage treatment combined with topical cactus and aloe cold compresses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Massage treatment or cactus and aloe cold compresses alone
Number of subjects: 0
Study: 25139884

Group type: EXPERIMENTAL
Intervention: Increased serum calcium levels during follow-up (higher tertile of change: 0.52 ± 0.13 mg/dL)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Albumin-adjusted serum calcium analyzed as a continuous variable
Number of subjects: 77
Study: 21785860

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 8 ng/kg/min iv epoprostenol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19563665

Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 221

Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 221
Study: 17883462

Group type: EXPERIMENTAL
Intervention: Azithromycin plus loperamide (500 mg)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Azithromycin alone (500 mg or 1000 mg)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Azithromycin alone
Number of subjects: 176
Study: 14744822

Group type: EXPERIMENTAL
Intervention: Immersion in water
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard augmentation (amniotomy and intravenous oxytocin)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard augmentation
Number of subjects: 99
Study: 12471288

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (low- and moderate-intensity, 25-50% HRR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 18
Study: 10366085

Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap with phacotrabeculectomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap with phacotrabeculectomy
Number of subjects: 44
Study: 7656936

Group type: EXPERIMENTAL
Intervention: Budesonide (1.2 mg) once daily via a Nebuhaler for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2523653

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 800

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 800
Study: 1155428

Group type: EXPERIMENTAL
Intervention: Physiometrics blood pressure recorder with broad, hard surrounding cuff
Number of subjects: 443

Group type: COMPARATOR
Intervention: Standard cuff sizes selected according to recommended criteria (Baumanometer)
Number of subjects: 443
Study: 31356973

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Conservative treatment (CT)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Both PVP and CT
Number of subjects: 544
Study: 28071840

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 25333246

Group type: EXPERIMENTAL
Intervention: Maternal exercise program (land/aquatic activities, aerobic and muscular conditioning), 60 min on land and 50 min in water, three times per week, n = 101
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual standard care, n = 156
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Maternal exercise program
Number of subjects: 342
Study: 23009672

Group type: EXPERIMENTAL
Intervention: Home Independence Program (HIP)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual home-care services
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 150 from each group
Number of subjects: 750
Study: 21463380

Group type: EXPERIMENTAL
Intervention: Chairside tribochemical silica coating/silane coupling system (CoJet group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No surface treatment (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laboratory tribochemical silica coating/silane coupling system (Rocatec group)
Number of subjects: 24
Study: 19231993

Group type: EXPERIMENTAL
Intervention: HBV-active ART
Number of subjects: 36
Study: 17042769

Group type: EXPERIMENTAL
Intervention: G‐CSF administration from day +5 (arm A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Delayed, individually determined G‐CSF administration (arm B)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (arm C)
Number of subjects: 106

Group type: COMPARATOR
Intervention: G‐CSF (arm A and B)
Number of subjects: 106
Study: 15222820

Group type: EXPERIMENTAL
Intervention: Autobiographical retrieval practice
Number of subjects: 43
Study: 11425416

Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccine (7.5 microg doses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (30 microg doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccine (30 microg doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccine
Number of subjects: 65